Alan Kaufman MD LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,994	5
2024	Research	$4,978	14
2023	Research	$2,791	7
2022	Research	$8,344	28
2021	Research	$1,061	2
2020	Research	$2,122	4
2019	Research	$19,186	10

Breakdown

Who paid Research payments · program years 2019–2025

Regeneron Pharmaceuticals, Inc. $25,069 68 payments
AstraZeneca UK Limited $8,154 1 payment
AstraZeneca Pharmaceuticals LP $7,253 1 payment

Studies the money was for Research payments · program years 2019–2025

A Prospective Observational Study of Patients Receiving Dupixent for Atopic Dermatitis $18,107 54 payments
Observational Study of Obstructive Lung Disease NOVELTY $8,154 1 payment
The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $7,253 1 payment
A Prospective Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis $6,962 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.